Overview
This entry, listed under Orphanet code 331244, is classified as 'OBSOLETE' — meaning it is no longer an active or recognized disease category in the Orphanet rare disease database. It was previously used as a grouping term for certain immunodeficiency conditions where the main problem was the body's inability to make enough antibodies (also called immunoglobulins). Antibodies are proteins made by the immune system to fight infections caused by bacteria, viruses, and other germs. When the body cannot produce enough of these protective proteins, a person becomes more vulnerable to frequent and sometimes severe infections. Because this classification is obsolete, patients who were once grouped under this term have likely been reclassified into more specific diagnoses. These may include conditions such as common variable immunodeficiency (CVID), selective IgA deficiency, specific antibody deficiency, or other well-defined primary antibody deficiency syndromes. If you or a family member was given this diagnosis, it is important to work with an immunologist or clinical geneticist to determine the current, more precise diagnosis. A more specific diagnosis can guide better treatment decisions, genetic counseling, and access to clinical trials. Treatment for antibody deficiency conditions generally involves immunoglobulin replacement therapy (given through an IV or under the skin), preventive antibiotics, and careful monitoring for infections and related complications.
Key symptoms:
Frequent sinus infectionsRepeated ear infectionsRecurring pneumonia or lung infectionsChronic diarrheaFrequent skin infectionsSlow recovery from common illnessesUnexplained weight loss or poor growth in childrenSwollen lymph nodesFatigue and low energyBronchiectasis (permanent damage to the airways from repeated infections)
Variable
Can be inherited in different ways depending on the underlying gene
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
4 eventsOctapharma — PHASE3
Grifols Therapeutics LLC — PHASE3
Monash University — PHASE2, PHASE3
National Institute of Allergy and Infectious Diseases (NIAID)
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects.
3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Specialists
View all specialists →No specialists are currently listed for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects.
Start the conversation →Latest news about OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects
No recent news articles for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Has my diagnosis been updated to a more specific condition since this category is now obsolete?,What specific type of antibody deficiency do I have, and is genetic testing recommended?,Do I need immunoglobulin replacement therapy, and if so, which method is best for me?,Are there any vaccines I should avoid or that my family members should receive?,How often should I have my immunoglobulin levels and lung function checked?,What signs of complications should I watch for at home?,Are there any clinical trials or new treatments I should know about?
Common questions about OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects
What is OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects?
This entry, listed under Orphanet code 331244, is classified as 'OBSOLETE' — meaning it is no longer an active or recognized disease category in the Orphanet rare disease database. It was previously used as a grouping term for certain immunodeficiency conditions where the main problem was the body's inability to make enough antibodies (also called immunoglobulins). Antibodies are proteins made by the immune system to fight infections caused by bacteria, viruses, and other germs. When the body cannot produce enough of these protective proteins, a person becomes more vulnerable to frequent and s
Are there clinical trials for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects?
Yes — 3 recruiting clinical trials are currently listed for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.